Helix BioMedix Inc
Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington.
Helix BioMedix Inc - Asset Resilience Ratio
Helix BioMedix Inc (HXBM) has an Asset Resilience Ratio of 0.00% as of September 2012. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2021)
This chart shows how Helix BioMedix Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Helix BioMedix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Helix BioMedix Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Helix BioMedix Inc Industry Peers by Asset Resilience Ratio
Compare Helix BioMedix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Helix BioMedix Inc (2006–2021)
The table below shows the annual Asset Resilience Ratio data for Helix BioMedix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 25.84% | $1.25 Million | $4.84 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $2.97 Million | -- |
| 2010-12-31 | 0.00% | $0.00 | $5.23 Million | -- |
| 2009-12-31 | 0.00% | $0.00 | $2.01 Million | -- |
| 2008-12-31 | 36.43% | $984.84K | $2.70 Million | +1.81pp |
| 2007-12-31 | 34.62% | $700.00K | $2.02 Million | +2.53pp |
| 2006-12-31 | 32.09% | $980.00K | $3.05 Million | -- |